2. Membrane Transporter/Ion Channel
  3. P-glycoprotein
  4. Dofequidar sesquifumarate

Dofequidar sesquifumarate  (Synonyms: MS-209 sesquifumarate)

目录号: HY-17013D
产品使用指南 技术支持

Dofequidar (MS-209) sesquifumarate 是一种具有口服活性喹啉化合物，可阻断 P-糖蛋白 (P-gp) 和多药耐药相关蛋白-1 (MDR-1)。Dofequidar sesquifumarate 对多药耐药肿瘤细胞具有很强的逆转作用。Dofequidar sesquifumarate 竞争性抑制 ABCB1/P-gp、ABCC1/MRP-1，阻断化疗剂的流出，增加癌细胞中的化疗剂浓度，增强化疗效果。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Dofequidar sesquifumarate Chemical Structure

Dofequidar sesquifumarate Chemical Structure

CAS No. : 158681-49-3

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Dofequidar sesquifumarate 的其他形式现货产品:

Customer Review

Other Forms of Dofequidar sesquifumarate:

Dofequidar sesquifumarate 相关抗体

Top Publications Citing Use of Products
Cell Viability Assay

    Dofequidar sesquifumarate purchased from MCE. Usage Cited in: Am J Transl Res. 2020 May 15;12(5):1807-1823.  [Abstract]

    CCK-8 assay showing a significantly lower cisplatin IC50 for the P-gp inhibitor Dofequidar fumarate (5 μM) treatment group compared with the vehicle control group in MG-63 and MNNG/HOS cells.

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Dofequidar (MS-209) sesquifumarate is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar sesquifumarate has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar sesquifumarate competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect[1][2].

    体外研究
    (In Vitro)

    Dofequidar sesquifumarate 在人小细胞肺癌 SBC-3/ADM 和 SBC-3 细胞体外增殖和药敏实验中，3-10 μM 可完全逆转 SBC-3/ADM 细胞对 Etoposide (VP-16) (HY-13629)、Adriamycin 和 Vincristine (HY-N0488) 的多药耐药性，对 SBC-3 细胞敏感性影响较小[1]。
    Dofequidar sesquifumarate 在人小细胞肺癌 SBC-3/ADM 和 SBC-3 细胞 P-gp 表达分析实验中，未改变 SBC-3 细胞 P-gp 表达，SBC-3/ADM 细胞本身表达 P-gp[1]。
    Dofequidar sesquifumarate 在多种癌细胞系的 SP 细胞分选实验中，以剂量依赖性方式降低侧群 (SP) 细胞的比例[2]。
    Dofequidar sesquifumarate 在细胞内药物积累实验中增加 K562/BCRP 细胞中 ABCC1⁄MDR相关蛋白 (MRP) 的细胞内浓度[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Dofequidar sesquifumarate 相关抗体:
    体内研究
    (In Vivo)

    Dofequidar（200 mg/kg；口服；从接种肿瘤细胞后第 10 或 14 天开始，共 4 次给药）sesquifumarate 在 NK 细胞耗竭的 SCID 小鼠（接种 SBC-3/ADM 或 SBC-3 细胞）模型中，与 Etoposide (VP-16) (HY-13629) 或 Adriamycin 联合使用显著抑制 SBC-3/ADM 细胞向多个器官的转移[1]。
    Dofequidar（200 mg/kg；口服；在 Irinotecan (CPT-11) (HY-16562) 注射前 30 分钟给药，与 Irinotecan 一同在第 0、4、8 天给药）sesquifumarate 在接种 HeLa SP 细胞的裸鼠模型中，与 Irinotecan 联合使用显著减小肿瘤体积[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 6- to 8-week-old male severe combined immunodeficiency (SCID) mice, depleted of natural killer (NK) cells by intraperitoneal injection of TM-β1 Ab (1 mg/mouse) 2 days before tumor inoculation, and then inoculated intravenously with SBC-3 or SBC-3/ADM cells[1]
    Dosage: 200 mg/kg
    Administration: Orally administered; the mice inoculated with SBC-3 cells were treated on days 14, 15, 21, and 22; the mice inoculated with SBC-3/ADM cells were treated on days 10, 11, 17, and 18.
    Result: Combined use with Etoposide (VP-16) (HY-13629) or Adriamycin can significantly inhibit metastasis formation by SBC-3/ADM cells to the liver, kidneys, and lymph nodes, and the weight of the liver of the treated mice was significantly less than that of other groups.
    Animal Model: 5- to 6-week-old female BALB/c-nu/nu (nude) mice, inoculated subcutaneously with HeLa SP cells[2]
    Dosage: 200 mg/kg
    Administration: Orally administered 30 minutes before intravenous injection of Irinotecan (67 mg/kg); on days 0, 4, and 8.
    Result: Co-treatment with Irinotecan drastically decreased the tumor volume.
    分子量

    1311.39

    Formula

    C30H31N3O3.3/2C4H4O4
    CAS 号
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    纯度 & 产品资料
    参考文献

    Dofequidar sesquifumarate 相关分类

    • 摩尔计算器

    • 稀释计算器

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量   浓度   体积   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Dofequidar sesquifumarate158681-49-3MS-209 sesquifumarateP-glycoproteinP-gpPgpMultidrug resistance protein 1MDR1ATP-binding cassette sub-family B member 1ABCB1Cluster of differentiation 243CD243MS-209Inhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Dofequidar sesquifumarate
    目录号：
    HY-17013D
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z